Abstract Objective: To observe the influence of dipeptidyl peptidase 4 (DPP-4) inhibitor on serum levels of betatrophin and lipidmetabolism of women with polycystic ovary syndrome (PCOS) initial diagnosed. Methods: 225 women with PCOS initial diagnosed were randomly divided into group A, B and C (75 cases in each group). The women in group A were treated by sitagliptin (DPP-4 inhibitor), the women in group B were treated by sitagliptin combined with diane-35, and the women in group C were treated by metformin combined withdiane-35. All the women were treated for 3 months. Body mass index (BMI), waist-to-hip ratio (WHR), glycolipid metabolism indexes, sex hormones levels and serum betatrophin levels were compared before and after treatment. Results: After treatment, the menstrual improvement of women in group A and B was better than that of women in group C, the improvement of acne or hirsutism of women in group B and C was better than that of women in group A (P<0.05). The values of BMI and WHR of women in group A and B were significant lower than those of women in group C(P<0.05).The levels of HbAlc, PPGE, MAGE, HOMA-IR, TC, TG, LDL-C and betatrophin of women in group A and B were significant lower than those of women in group C, and the level of HOMA-βwas significant higher (P<0.05), while there were no significant different in the levels of WHR, FPG, 2hPG, MBG, FINS, and HDL-C among the three groups (P>0.05). The levels of FSH, LH, T and A of women in group A and B were significant lower than those of women in group C (P<0.05), while the E2 and P levels had no significant different among the three groups (P>0.05). There was no any woman with adverse reaction in group A and B, which was significant lower than that (16.0%) of women in group C (P<0.05). Conclusion: DPP-4 inhibitor is safe and effective for treating women with PCOS initial diagnosed, which can alleviate IR, hyperandrogenemia, and glycolipid metabolism disorder of women.
|
|
|
|
|
|
